Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Zevra Therapeutics (NasdaqGS: ZVRA) granted stock options to purchase an aggregate 92,200 common shares to four new employees under its 2023 Employment Inducement Award Plan. The options vest over four years, starting with 25% after one year, in accordance with Nasdaq Rule 5635(c)(4).

Market Context

Recent insider activity was net selling, with 89,523 shares sold and none bought, adding market cont...

Analysis

Recent insider activity was net selling, with 89,523 shares sold and none bought, adding market context to this employee grant. The vesting schedule provides timing detail, while the article gives no exercise price.

Key Figures

Inducement shares: 92,200 shares Recipients: 4 employees Vesting period: 4 years +1 more

4 metrics

Inducement shares 92,200 shares Options granted to four new employees

Recipients 4 employees New employees receiving inducement awards

Vesting period 4 years Each inducement award

Initial vesting 25% On the first anniversary of the employee's start date

Historical Context

5 past events · Latest: Aug 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	Q2 earnings report	Positive	+12.8%	Revenue growth, profitability, and cash balance accompanied the quarterly report.
Aug 04	Conference presentation	Neutral	+4.6%	Conference presentation scheduling preceded a positive price reaction without reported operating or clinical results.
Aug 03	Real-world clinical data	Positive	+5.7%	Four-year real-world MIPLYFFA data publication preceded a positive price reaction.
Jul 24	European regulatory opinion	Negative	-23.9%	Negative CHMP opinion on European arimoclomol application preceded a sharp decline.
Jul 22	Q2 call scheduling	Neutral	-2.5%	Results-call scheduling preceded a negative price reaction without reported financial results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive earnings and clinical-data announcements were followed by gains, while negative regulatory news was followed by a decline; neutral notices showed mixed reactions.

Key Terms

inducement awards, nasdaq rule 5635(c)(4), vesting

3 terms

inducement awards financial

"granted ... (the “Inducement Awards”) to four new employees"

Inducement awards are special bonuses given to new employees to encourage them to join a company, often in the form of stock or money. They matter because they can motivate talented people to choose one company over another and help align their success with the company's growth. Think of it like a signing bonus to seal the deal.

nasdaq rule 5635(c)(4) regulatory

"in accordance with Nasdaq Rule 5635(c)(4)."

NASDAQ Rule 5635(c)(4) is a listing standard that requires a company to obtain shareholder approval before issuing a substantial number of new shares or convertible securities in certain financing or insider-related transactions that would materially dilute existing holders. It matters to investors because the vote gives shareholders a check on deals that could significantly change ownership stakes or voting power—like a homeowners’ association approving a major renovation that affects the whole neighborhood’s value.

vesting financial

"with 25% vesting on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living with rare diseases, today announced that the Company has granted options to purchase an aggregate of 92,200 shares of the Company’s common stock (the “Inducement Awards”) to four new employees pursuant to the Company’s 2023 Employment Inducement Award Plan. Each Inducement Award vests over four years, with 25% vesting on the first anniversary of the employee’s start date, and the remainder vesting in three equal annual installments thereafter (subject to each such employee’s continued employment on each vesting date).

Each Inducement Award was approved by the Company’s Compensation Committee and granted as an inducement material to the individual entering into employment with Zevra, in accordance with Nasdaq Rule 5635(c)(4).

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. is a commercial-stage company with a late-stage pipeline committed to redefining what is possible in bringing life-changing therapies to people living with rare diseases. The Company is focused on broadening access through geographic expansion opportunities, progressing its pipeline toward key milestones, and delivering meaningful therapeutics. The commercialization of its lead product, marketed in the U.S. for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a strong corporate foundation and validates its ability to advance therapies from development to market. Zevra's vision is realized through disciplined execution of its strategic plan and core values — patient centricity, integrity, accountability, innovation, and courage — which guide its efforts to deliver long-term value.

For more information, please visit www.zevra.com or follow us on X and LinkedIn.

Caution Concerning Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding its ability to advance therapies from development to market and to deliver long-term value. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the “Risk Factors” section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 9, 2026, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

Investor Contact

Nichol Ochsner 
+1 (732) 754-2545 
nochsner@zevra.com  

Media Contact

Julie Downs
+1 (508) 246-3230 
jdowns@zevra.com 

FAQ

What inducement grants did Zevra Therapeutics (ZVRA) announce on August 21, 2026?

Zevra Therapeutics announced stock option inducement grants covering 92,200 common shares for four new employees. According to Zevra Therapeutics, these options were issued under its 2023 Employment Inducement Award Plan and are intended as material incentives for the individuals to join the company.

How do the Zevra Therapeutics (ZVRA) inducement stock options vest for the new employees?

The inducement options vest over four years, with 25% vesting after the first year of employment. According to Zevra Therapeutics, the remaining 75% vests in three equal annual installments, contingent on each employee’s continued employment on the applicable vesting dates.

Why were the Zevra Therapeutics (ZVRA) inducement awards granted under Nasdaq Listing Rule 5635(c)(4)?

The options were granted as inducement awards considered material to the individuals entering employment with Zevra. According to Zevra Therapeutics, the Compensation Committee approved these grants in accordance with Nasdaq Listing Rule 5635(c)(4) and the company’s 2023 Employment Inducement Award Plan.

How many new employees received Zevra Therapeutics (ZVRA) inducement stock options and under which plan?

Four new employees received inducement stock options under Zevra Therapeutics’ 2023 Employment Inducement Award Plan. According to Zevra Therapeutics, these grants cover an aggregate of 92,200 common shares and were specifically structured to support recruitment of new team members.

What stage of development is Zevra Therapeutics (ZVRA) and what is its lead product focus?

Zevra Therapeutics describes itself as a commercial-stage company with a late-stage pipeline. According to Zevra Therapeutics, its lead product is marketed in the U.S. for Niemann-Pick disease type C, a rare progressive neurodegenerative disease, supporting its corporate foundation.